<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2643">A total of 29 RCTs (n = 2737) met inclusion criteria, including 6 new trials since our last update. When the results of trials reporting infections were aggregated, probiotics were associated with a significant reduction in infections (RR 0.82, 95 % CI 0.69, 0.97, P = 0.02; heterogeneity I2 = 41 %), and particularly among patients with higher risk of death (RR 0.75, 95 % CI 0.61, 0.99, P = 0.04; I2 = 58 %; Fig. 
 <xref rid="Fig76" ref-type="fig">76</xref>). Moreover, probiotics were associated with a significant reduction in the incidence of VAP (RR 0.74, 95 % CI 0.58, 0.96, P = 0.02, I2 = 29 %). Finally, probiotics had no effect on mortality, diarrhea, and hospital LOS
</p>
